clinical trial · NCT06449352
Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost
Westlake Eye Specialists·phase4·completed·n = 100
Normal Tension GlaucomaNetarsudilBrimonidine
brief summary
A randomized, multicenter, investigator-masked prospective study of NTG patients currently on latanoprost 0.005% monotherapy, to study the effect of IOP change with the introduction of netarsudil 0.02% vs brimonidine 0.1%. Subjects will be assessed at a screening visit, and 1 follow-up visit. Clinical evaluations will include visual acuity and IOP .
started
Jun 13, 2024
primary completion
Sep 22, 2025
completion
Sep 22, 2025
last updated
Oct 22, 2025
official title
Effect of the Addition of Netarsudil 0.02% vs. Brimonidine 0.1% in Normal Tension Glaucoma Patients Currently on Latanoprost 0.005%
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol